Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
About Applied Nanotech Holdings, Inc.
Applied Nanotech Holdings, Inc. is a premier research and commercialization organization focused on solving problems at the molecular level. Its team of PhD level scientists and engineers work with companies and other organizations to solve technical impasses and create innovations that will create a competitive advantage. The business model is to license patents and technology to partners that will manufacture and distribute products using the technology. Applied Nanotech has over 300 patents or patents pending. Applied Nanotech’s website is http://www.appliednanotech.net.
EZDiagnostiX
EZDx is one of our most exciting areas with immediate market opportunities. To recap our activities to date, we formed EZDx in May 2012 to commercialize our sensor technology which is an important part of our long term commercialization strategy. This strategy requires different human resources and additional financial resources to shift from prototype development to market commercialization where we can capture greater value. In terms of human resources, we took the first step last year when we hired Alan Jernigan, a proven executive with sales, marketing, and commercialization experience, particularly in medical diagnostics and medical devices.
Every day this stock gets more appealing. Once the Citrus testing platforms get under way. PPS pop
:( missed the first push :(
W0w just checked my account and what acouple months make. Picked up 20k shares @ .28s
After-hours PR/8K out. iHUB does not accurately release all news.
1. http://ir.stockpr.com/amarantus/company-news/detail/644/amarantus-bioscience-modifies-business-structure-to-support-product-development-strategy
2. http://biz.yahoo.com/e/130404/ambs8-k.html
Speculation of 800 million in revenue starting this year through the diagnostics, and then 250 million precedent of GDNF value for MANF. Once the market understands what this baby biotech is the company's PPS will be .5-.1 by summer or before.
The squeeze in conjunction with PR may propel this to the national exchange faster, then we all think. Ducks are realigned again for the next stage.
Yes, Market cap should be 100+million, but we will get their very soon. The diagnostics will propel this baby biotech back to .1s
I believe their CUSIP change in the near future will squeeze these guys. Last CUSIP in Jan the stock went to .194. PR on diagnostics will be ,25-,3 no problem.
Without a doubt the DD speaks for itself. Nasdaq material board of directors.
AMBS will well over .194 this time, especially with diagnostics going to phase2.
Especially, AMBS's diagnostics which are both about to go to Phase 2, then CLIA certified. After that commercialization this year!
Check out AMBS's last run runs:
1)AMBS went from 0.004 to 0.02
2)AMBS went from 0.0048 to 0.087
3)AMBS went from 0.017 to 0.195
4)AMBS went from .04s to ?
Thanks Lew, the run to .19 was fantastic.
Quote:
1)AMBS went from 0.004 to 0.02
2)AMBS went from 0.0048 to 0.087
3)AMBS went from 0.017 to 0.195
4)AMBS went from .04s to ?
AMBS 2 huge afterhours PR Chart setting up for .19
AMBS 2 huge PRs afterhours setting up for .19 run + Chart here: http://ir.stockpr.com/amarantus/company-news/detail/644
AMBS chart setting up for .19+ http://ir.stockpr.com/amarantus/company-news/detail/644
AMBS 2 huge afterhours PR out.
AMBS another PR still aiming for uplist on track
AMBS another CUSIP change like in DEC flew to ,19 http://ir.stockpr.com/amarantus/company-news/detail/644
AMBS NEWS OUT HUGE. LIKE LAST RUN TO .19
CEO still has eyes on up-listing. The diagnostics will propel PPS next week well over .1
"The Series C Convertible Preferred Stock has no anti-dilution provisions, can only be issued to officers and directors of the Company, is convertible into a cumulative total of 750,000 common shares and is automatically convertible into common stock upon listing of the Company’s common stock to a national stock exchange"
AMBS Market Capitalization is now 24million.
Thanks Muga AMBS is up 100% since yesterday!!
Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On April 1, 2013 Amarantus BioScience, Inc. (the “Company”) filed a Certificate of Designation with the State of Nevada creating a series of Series C Convertible Preferred Stock consisting of 750,000 shares. On April 2, 2013 the Company filed the Certificate of Designation with the State of Nevada formally creating the previously disclosed series of Series B Convertible Preferred Stock consisting of 2,500,000 shares. A copy of the Series C Certificate of Designation and the Series B Certificate of Designation filed herewith as Exhibit 3.1 and Exhibit 3.2, respectively.
The Series B Convertible Preferred Stock has no anti-dilution provisions, can only be issued to officers, directors and advisors of the Company, and cannot be converted into common stock, transferred, sold or disposed of in any manner for 24 months.
The Series C Convertible Preferred Stock has no anti-dilution provisions, can only be issued to officers and directors of the Company, is convertible into a cumulative total of 750,000 common shares and is automatically convertible into common stock upon listing of the Company’s common stock to a national stock exchange.
Item 8.01 Other Events.
On April 3, 2013, the Company entered into a Settlement Agreement and Release with On Assignment Staffing Services, Inc. (“On Assignment”) pursuant to which the Company will pay On Assignment an aggregate of $45,000 over a period of time and On Assignment will dismiss its lawsuit against the Company currently pending in Santa Clara County, California. The Company is no longer subject to any legal proceedings.
On April 4, 2013, the Company announced that it was adopting a holding company structure with separate business units in order to more effectively develop its various assets and would be changing its name to Amarantus Bioscience Holdings, Inc. Concurrently, the Company has requested a change in its Committee on Uniform Security Identification Procedures (CUSIP) number. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
Tell that to the algos.....
This is a poker game you don't show your hand on l2
Thanks MUGA. AMBS is doing nicely!
AMBS just joined "Mapping the brain" organization Free OBAMA MONEY! http://www.neurotechindustry.org/
Look for .0639 in the 20-45 minutes.